

Understanding IL-4: Outlook and Potentials

Midterm Project

Oct. 19th, 2024

Mentee: Molly Liu

Mentor: Thomas Yuan

01

Understanding
AD and Its
Market
Potentials

02


Features and
Highlights of
IL-4

03


Future Trends
and Potentials

Atopic Dermatitis is a Fast-Growing Disease With High Treatment Cost...

Symptoms




Statistics



Urbanization includes factors such as **air pollution** and **mental stress**. With the pace of life and urbanization rate in China continues to rise, the number of AD patients is **likely to further increase**.

...Leading to a Market With Enormous Size and Opportunities



Source: PharmaCube; Mao, Dandan, et al. "Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study." Chinese medical journal 136.5 (2023): 604-606; Guo, Yifeng, et al. "Prevalence of atopic dermatitis in Chinese children aged 1–7 ys." Scientific Reports 6.1 (2016): 29751.

IL-4 Biologics Have The Best Efficacy in Treating M-S AD and Many Beyond...

Trial Data

Key Observations

| | 康悦达® 司美格鲁肽注射液 | DUPIXENT® (dupilumab) injection 200mg · 300mg | CIBINQO® (abrocitinib) tablets |
|-------------------------------|--|--|--|
| Originator |  KeyMed Biosciences |  sanofi |  Pfizer |
| MoA | IL-4 | IL-4 | JAK1 |
| Dosing | Injection; 300 mg; Q2W (1 dose) | Injection; 300 mg; Q2W (1 dose) | Oral; 100 mg; Daily |
| Efficacy Results (IGA 0/1) | 44% ...after 16 weeks | 38% ...after 16 weeks | 36% ...after 12 weeks |
| Annual OOP Price (RMB) | 39,816 | 20,020 | 28,470 |
| Approved Indications | 1 | 5 | 1 |
| Safety (FDA Warning) | No | No | Yes |



AD is a chronic disease and requires long-term maintenance. The introduction of **injection pens** allows patients to self-administer the drug, making it more convenient to use




Inclusion of Dupixent on the NRDL reimbursement list significantly **reduces the OOP price** for patients and **improves overall patient access**



Sanofi's clinical trials have identified more clinical possibilities for Dupixent in other disease areas, and the **potential of IL-4 beyond AD treatment remains tremendous**

...With Many IL-4 Products on Track to Enter the Competition for M-S AD Treatment



SOURCE: Desktop research; PharmaCube Data

Future of IL-4 Biologics Remains Bright For Several Reasons

Present Issues



Key Observations



Sustained Improvement in Diagnosis Rate

Currently, the aggregate diagnosis rate for AD in China remains relatively low (70%). Many patients often confuse AD with eczema and therefore do not seek proper treatment. With increased efforts to educate patients, the number of AD patients treated with IL-4 biologics is likely to further increase



Higher Prevalence Rate Driven by Urbanization

Previous epidemiological studies have shown that the prevalence of AD is closely associated with a more stressful lifestyle. As China's urban population continues to grow, the prevalence rate of AD is expected to continue to increase, driving the use of IL-4 biologics.



Shifting Treatment Preference and Understanding

Traditional Chinese medicine still plays an important role in the treatment of dermatologic diseases. However, with the growing acceptance of Western treatments among patients, as well as the introduction of injection pens, IL-4 biologics are expected to gain wider acceptance

Q&A

